Array ( [0] => 29444 [1] => 29213 [2] => 28060 ) Array ( [0] => 29444 [1] => 29213 [2] => 28060 ) Array ( [0] => 29050 [1] => 29045 [2] => 29025 ) Array ( [0] => 29050 [1] => 29045 [2] => 29025 )

Last Updated: 19/06/2024

Development of Plasmodium vivax vaccine effective both for protection and transmission blocking

Objectives

*Original title and abstract were machine translated from Japanese.

This study proposes a general-purpose purely domestic vaccine platform for emerging and re-emerging infectious diseases that may cause outbreaks.

Principal Institution

Kanazawa University, Japan

Principal Investigators / Focal Persons

Shigeto Yoshida

Partner Institutions

Jichi Medical University, Japan
Musashino University (MU), Japan
University of Toyama, Japan

Rationale and Abstract

The study will develop a vivax vaccine based on the unique vaccine platform (LC16m8delta / AAV) consisting of the vaccinia virus vaccine strain LC16m8delta and the adeno-associated virus AAV. An LC16m8delta / AAV vaccine has been prepared into which a target antigen gene was introduced to prevent infection and prevent transmission of Plasmodium vivax. Animal immunity-Infection challenge experiment (mouse model) and artificial membrane mosquito blood sucking experiment using infected person’s blood were conducted, and numerical targets of infection protection effect> 90% and transmission prevention effect> 90% were set as milestones for 3 years.

External reference

Project details

Thematic Categories

P. vivax
Vaccines (Immune Correlates)

Date

Apr 2022 — Mar 2025

Total Project Funding

$146,578

Funding Details

Japan Society for the Promotion of Science (JSPS), Japan

Grant ID: 22H03116

JPY 17.42M